Post-Marketing Study Of Emergency Contraceptive Ella Would Be Challenging

FDA and its Reproductive Health Drugs Advisory Committee could not agree on the shape that post-marketing surveillance of HRA Pharma's emergency contraceptive Ella (ulipristal acetate) should take